#Aids2026: Daily pill. Monthly pill. Six-monthly jab. Why choice matters
For the first time, Merck has granted generic manufacturers, including three African companies, permission to produce an investigational monthly HIV prevention pill, alimatravir, before its final studies are complete. This move aims to accelerate access to the medicine, potentially offering a crucial new option alongside existing daily pills and six-monthly injections, and boosting African pharmaceutical industrialisation.
Black News 
For the first time, Merck has granted generic manufacturers, including three African companies, permission to produce an investigational monthly HIV prevention pill, alimatravir, before its final studies are complete. This move aims to accelerate access to the medicine, potentially offering a crucial new option alongside existing daily pills and six-monthly injections, and boosting African pharmaceutical industrialisation.
